VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ELVN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ELVNEnliven Therapeutics, Inc.
$50.85$3.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksELVNQuarterly Financials

Enliven Therapeutics, Inc. (ELVN) Quarterly Financials

120+ quarters historyFree accessUpdated daily

Enliven Therapeutics, Inc. (ELVN) quarterly income statement — complete revenue, gross profit & net income history

ELVN Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricQ1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23Q1'23Q4'22Q3'22Q2'22Q1'22Q4'21Q3'21Q2'21
Sales/Revenue00000000000000000000
Revenue Growth %--------------------
Cost of Goods Sold14K46K000000000000000024K25K
COGS % of Revenue--------------------
Gross Profit-14K-46K0000000000000000-24K-25K
Gross Margin %--------------------
Gross Profit Growth %--------------100%100%100%---
Operating Expenses27.82M34.24M25.1M28.58M31.69M26.9M27.07M24.6M25.99M22.73M24.25M20.13M16.42M10.16M10.93M9.02M8.68M8.39M13.63M13.14M
OpEx % of Revenue--------------------
Selling, General & Admin7.14M13.04M6.87M7.09M6.8M6.17M5.81M5.78M6.02M4.82M3.34M3.65M4.54M1.97M3.1M1.08M1.62M1.53M3.24M3.07M
SG&A % of Revenue--------------------
Research & Development20.69M21.25M18.23M21.49M24.89M20.72M21.26M18.83M19.97M17.91M19.61M15.18M11.88M8.2M7.83M7.94M7.06M6.86M10.4M10.07M
R&D % of Revenue--------------------
Other Operating Expenses00000000001000K1000K00000000
Operating Income-27.82M-34.28M-25.1M-28.58M-31.69M-26.9M-27.07M-24.6M-25.99M-22.73M-24.25M-20.13M-16.42M-10.16M-10.93M-9.02M-8.68M-8.39M-13.66M-13.17M
Operating Margin %--------------------
Operating Income Growth %12.21%-27.47%7.29%-16.18%-21.96%-18.33%-11.63%-22.2%-58.28%-123.64%-121.77%-123.31%-89.19%-21.06%19.95%31.54%15.58%27.32%-9.32%-27.83%
EBITDA-27.81M-34.24M-25.03M-28.5M-31.62M-26.82M-26.99M-24.52M-25.91M-22.65M-24.17M-20.06M-16.35M-10.1M-10.87M-8.96M-8.64M-8.36M-13.63M-13.14M
EBITDA Margin %--------------------
EBITDA Growth %12.05%-27.68%7.24%-16.22%-22.04%-18.39%-11.66%-22.26%-58.45%-124.29%-122.27%-123.78%-89.27%-20.77%20.25%31.8%15.76%27.46%-9.35%-27.9%
D&A (Non-Cash Add-back)14K46K62K81K74K80K80K78K79K78K78K74K67K64K60K52K39K33K24K25K
EBIT-27.82M-34.28M-20.15M-28.58M-31.69M-26.9M-27.07M-24.6M-25.99M-22.73M-24.25M-20.13M-16.42M-10.16M-10.93M-9.02M-8.68M-8.39M-13.65M-13.16M
Net Interest Income4.2M4.62M4.95M3.25M3.2M3.72M3.84M4.09M3.25M3.37M3.49M3.41M1.69M613K380K127K9K3K30K48K
Interest Income4.2M4.62M4.95M3.25M3.2M3.72M3.84M4.09M3.25M3.37M3.49M3.41M1.69M613K380K127K9K3K30K48K
Interest Expense00000000000000000000
Other Income/Expense4.2M4.62M4.95M3.25M3.15M3.72M3.91M4.88M3.25M3.36M3.48M3.41M1.69M613K380K127K9K3K12K8K
Pretax Income-23.63M-29.67M-20.15M-25.34M-28.54M-23.18M-23.16M-19.72M-22.74M-19.37M-20.77M-16.72M-14.72M-9.55M-10.55M-8.89M-8.67M-8.39M-13.65M-13.16M
Pretax Margin %--------------------
Income Tax0000000232K000000000000
Effective Tax Rate %0%0%0%0%0%0%0%-1.18%0%0%0%0%0%0%0%0%0%0%0%0%
Net Income-23.63M-29.67M-20.15M-25.34M-28.54M-23.18M-23.16M-19.95M-22.74M-19.37M-20.77M-16.72M-14.72M-9.55M-10.55M-8.89M-8.67M-8.39M-13.65M-13.16M
Net Margin %--------------------
Net Income Growth %17.23%-27.99%12.99%-26.99%-25.53%-19.67%-11.49%-19.31%-54.43%-102.83%-96.79%-88.11%-69.85%-13.8%22.66%32.46%15.48%27.14%-9.85%-28.98%
Net Income (Continuing)-23.63M-29.67M-20.15M-25.34M-28.54M-23.18M-23.16M-19.95M-22.74M-19.37M-20.77M-16.72M-14.72M-9.55M-10.55M-8.89M-8.67M-8.39M-13.65M-13.16M
Discontinued Operations00000000000000000000
Minority Interest00000000000000000000
EPS (Diluted)-0.38-0.45-0.32-0.49-0.57-0.46-0.48-0.41-0.54-0.47-0.51-0.41-0.804.90-0.70-1.74-2.23-2.18-2.19-2.97
EPS Growth %33.33%2.17%33.33%-19.51%-5.56%2.13%5.88%0%32.5%-109.59%27.14%76.44%64.13%324.77%68.04%41.41%4.29%17.11%23.43%-25.32%
EPS (Basic)-0.38-0.45-0.32-0.49-0.57-0.46-0.48-0.41-0.54-0.47-0.51-0.41-0.804.90-0.70-1.74-2.23-2.18-2.19-2.97
Diluted Shares Outstanding62.8M56.66M62.09M52.11M50.05M49.86M48.27M48.08M42.05M41.13M41.03M40.96M18.52M6.57M6.57M6.57M6.57M6.57M6.22M4.43M
Basic Shares Outstanding62.8M56.66M62.09M52.11M50.05M49.86M48.27M48.08M42.05M41.13M41.03M40.96M18.52M6.57M6.57M6.57M6.57M6.57M6.22M4.43M
Dividend Payout Ratio--------------------